Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Michael A. Boyle"'
Publikováno v:
BMJ case reports. 14(8)
Ichthyosis prematurity syndrome (IPS) is a rare disorder of autosomal recessive inheritance. The cardinal features include prematurity, vernix like hyperkeratosis, eosinophilia and neonatal asphyxiation. This case report discusses the presentation an
Autor:
John G. Jiang, Susanna A. McColley, Michael P. Boyle, Jaime L. Rubin, Bonnie W. Ramsey, Michael W. Konstan, Gautham Marigowda, Montserrat Vera-Llonch, David Waltz, J. Stuart Elborn, Claire E. Wainwright
Publikováno v:
Journal of Cystic Fibrosis. 18:94-101
Background Improved lung function and fewer pulmonary exacerbations (PEx) were observed with lumacaftor/ivacaftor (LUM/IVA) in patients with cystic fibrosis homozygous for F508del. It is unknown whether PEx reduction extends to patients without early
Autor:
Tsigereda Tekle, Latetia Bryan, Mark T. Jennings, Karen C. Carroll, Nuntra Suwantarat, Michael P. Boyle, Mayer Rubin
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 90:296-299
Background Small-colony variants (SCVs) are a distinct phenotype of Staphylococcus aureus, known for their role in chronic, difficult to treat infections, including cystic fibrosis (CF) lung disease. The goal of this study was to characterize SCV MRS
Autor:
Brian Flanagan, Michael P. Boyle, Scott H. Donaldson, Pradeep Bhambhvani, Joseph M. Pilewski, Agathe Ceppe, Pamela L. Zeitlin, William D. Bennett, Kirby L. Zeman, Beth L. Laube, Peter J. Mogayzel, Steven M. Rowe, Landon W. Locke, Michael M. Myerburg, Timothy E. Corcoran
Publikováno v:
JCI Insight. 3
Background The ability to restore cystic fibrosis transmembrane regulator (CFTR) function with effective small molecule modulators in patients with cystic fibrosis provides an opportunity to study relationships between CFTR ion channel function, orga
Publikováno v:
BMJ Case Rep
A neonate, born at 24 weeks, underwent a patent ductus arteriosus ligation, with previous normal thyroid stimulating hormone (TSH) levels, developed severe hypothyroidism from topical exposure to iodine following a single surgical procedure at 28 day
Autor:
J. Stuart Elborn, David Waltz, Gautham Marigowda, Claire E. Wainwright, Xiaohong Huang, Bonnie W. Ramsey, Michael W. Konstan, Michael P. Boyle
Publikováno v:
The Lancet Respiratory Medicine. 4:617-626
Lumacaftor/ivacaftor combination therapy has shown clinical benefits in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation; however, pretreatment lung function is a confounding factor that potentially affects the efficacy and sa
Autor:
Mark T. Jennings, Marie Diener-West, Elliott C. Dasenbrook, Michael P. Boyle, Mary F. Rykiel, Rebecca Dezube, James F. Chmiel
Publikováno v:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 18(3)
Background The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in individuals with cystic fibrosis (CF) has increased significantly. While studies demonstrate that persistent MRSA infection in CF is associated with poor clinical outc
Autor:
Pamela L. Zeitlin, Marie Diener-West, C Conover Talbot, Karen Callahan, Bette Pollard, Michael P. Boyle, Noah Lechtzin, Seakwoo Lee
Cystic fibrosis (CF) lung disease progresses by a combination of airway inflammation, bacterial colonization, and infection. Airway inflammation is predominantly neutrophilic and complicates airway clearance therapies through cellular debris; excessi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::670dbf728c1dd2027d94375af7a7cbac
https://europepmc.org/articles/PMC5427734/
https://europepmc.org/articles/PMC5427734/
Autor:
Scott C. Bell, Susanna A. McColley, Michael P. Boyle, Michael W. Konstan, Gautham Marigowda, Steven M. Rowe, Ernst Rietschel, David Waltz, Xiaolei Li
Rationale: In a prior study, lumacaftor/ivacaftor treatment (≤28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not improve lung function.Objectives: To evaluate an optimized lumacaftor/ivacaftor dosing regimen with a lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5dbb467391cfe4be70eb1d4caf84f19
https://europepmc.org/articles/PMC5461999/
https://europepmc.org/articles/PMC5461999/
Overcoming the Cystic Fibrosis Sputum Barrier to Leading Adeno-associated Virus Gene Therapy Vectors
Autor:
Justin Hanes, Joshua Kays, Anthony J. Kim, Steven M. Rowe, Mia M Kanzawa, Nicholas Muzyczka, Jung Soo Suk, Michael P. Boyle, Benjamin S. Schuster, William B. Guggino
Publikováno v:
Molecular Therapy. 22(8):1484-1493
Gene therapy has not yet improved cystic fibrosis (CF) patient lung function in human trials, despite promising preclinical studies. In the human CF lung, inhaled gene vectors must penetrate the viscoelastic secretions coating the airways to reach ta